In Host Mutational Adaptation of Mycobacterium Tuberculosis Complex Strains During Tuberculosis Infection.

J Infect DisSep 23, 2026
Clinical ResearchInfectious Diseases

Helen Zhang, Naomi Medina-Jaudes, Alicia Forcada-Nadal et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined 5882 Mycobacterium tuberculosis complex (MTBC) genomes from 1044 patients to identify mutations associated with drug resistance during tuberculosis infection. The study found 21 genes and multiple operons significantly mutated, with fluoroquinolone resistance acquired more frequently than other anti-TB drugs, highlighting critical adaptive changes in MTBC strains.

Key findings

  • Identified 21 genes and 25 operons with significant mutations linked to drug resistance.
  • Fluoroquinolone resistance was acquired more frequently than resistance to other anti-TB drugs.
  • Previously reported candidate drug-resistance genes were confirmed in the analysis.
  • Mutations in virulence-related genes were frequently observed in host adaptations.

Why it matters

Understanding the mutations in MTBC strains during treatment can inform clinicians about the mechanisms of drug resistance and potential challenges in managing tuberculosis, particularly with fluoroquinolone therapies.

Source

PubMed · PMID 42047497

Published in J Infect Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.